Nikhil Lalwani
President and CEO at ANI Pharmaceuticals
Based on our first quarter performance and favorable demand trends across generics, chlorprofen gel and brands, we are raising our 2025 guidance for total revenues and adjusted non GAAP EBITDA. We now expect 2025 revenues of $768,000,000 to $793,000,000 which represents growth of 25% to 29% over 2024 versus our prior guidance of $756,000,000 to $776,000,000 We expect adjusted non GAAP EBITDA of $195,000,000 to $2.00 5,000,000 which reflects growth of 25% to 31% over 2024 versus our prior guidance of $190,000,000 to $200,000,000 Steve will provide more specifics on our updated guidance later in the call. Turning now to our first quarter results. Total revenues were $197,000,000 or $97,100,000 representing a year over year increase of 43% on an as reported basis and 32% on an organic basis, driven by exceptional performance for generics, continued strong growth for Cortrophin Gel and continued demand for our brands portfolio. Adjusted non GAAP EBITDA was $50,700,000 and adjusted non GAAP EPS was $1.7 Cortrophin Gel generated $52,900,000 in revenues during the quarter, up 43% over the first quarter of twenty twenty four.